PRISM BioLabLTD Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 206A?
Owner TypeNumber of SharesOwnership Percentage
Institutions-938,620-2.61%
Private Companies2,250,0006.26%
Individual Insiders3,533,0009.83%
Public Companies3,750,00010.4%
General Public11,295,32031.4%
VC/PE Firms16,065,10044.7%

Dilution of Shares: 206A only recently listed within the past 12 months


Top Shareholders

Top 12 shareholders own 71.34% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.2%
DBJ Capital Co., Ltd.
5,829,000JP¥2.0b0%74.79%
11%
WM PARTNERS Co., Ltd.
3,965,800JP¥1.4b0%66.78%
10.1%
DCI Partners Co., Ltd.
3,639,300JP¥1.3b-15.5%22.32%
7.32%
Life Sciences Venture Capital Co., Ltd.
2,631,000JP¥913.0m-11.3%100.0%
6.95%
Eli Lilly and Company
2,500,000JP¥867.5m0%no data
5.21%
Kiichiro Nakajima
1,872,000JP¥649.6m0%no data
3.48%
santec Holdings Corporation
1,250,000JP¥433.8m0%no data
3.48%
Newton Biocapital I, Pricaf Privée De Droit Belge Sa
1,250,000JP¥433.8m0%no data
2.78%
OHARA Pharmaceutical Co.,Ltd.
1,000,000JP¥347.0m0%no data
2.6%
Hideki Takeda
935,000JP¥324.4m0%no data
2.02%
Dai Takehara
726,000JP¥251.9m19,900%no data
0.15%
Simplex Asset Management Co., Ltd.
53,700JP¥18.6m0%0.01%